Skip to Main Content

Lyndra Therapeutics just raised $55 million from big-name investors like Gilead Sciences and the Bill and Melinda Gates Foundation — both of which have strong connections to HIV research and drug development.

But the company, which is developing once-a-week pills for a variety of diseases, cautions that HIV drugs aren’t necessarily next on its list.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!